Orthocell receives A$2.9m R&D tax incentive refund
US Nerve Repair Study Design Meets FDA Requirements
Perth, Australia; 16 December 2019: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell”, or the “Company”) is pleased to announce that it has received confirmation from the FDA that the proposed CelGro® nerve regeneration animal study protocol meets requirements to support the near term 510(k) submission. The Company has now accelerated ethics applications to commence the study in Q1 CY2020
Quarterly Report – December 2019
Key highlights for the quarter:
CelGro® accelerates dental implant treatments
•Patients regain normal oral function and enjoy a normal diet following CelGro® bone regeneration treatment.
•Patients experience a 40% reduction in dental implant treatment timeframe.
•Results further validate CelGro® as the superior medical device for bone and soft tissue repair.
•CelGro® continues to gain traction in Europe, with strategic partnering activities ongoing.
I've attached the announcement below.